Pre-order Enquiry
Request Free Sample
Global Antibody Drug Conjugate Therapeutics Market Research Report 2022
SKU ID : QYR-21414318 | Publishing Date : 03-Aug-2022 | No. of pages : 85
Detailed TOC of Global Antibody Drug Conjugate Therapeutics Market Research Report 2022
1 Report Overview1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody Drug Conjugate Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Mmunomedics Technology
1.2.3 Immunogen Technology
1.2.4 Seattle Genetics Technology
1.2.5 Others
1.3 Market by Application
1.3.1 Global Antibody Drug Conjugate Therapeutics Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Lymphoma
1.3.3 Leukemia
1.3.4 Multiple Myeloma
1.3.5 Skin Cancer
1.3.6 Colon Cancer
1.3.7 Glioblastoma
1.3.8 Pancreatic Cancer
1.3.9 Prostate Cancer
1.3.10 Solid Tumor
1.3.11 Breast Cancer
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Antibody Drug Conjugate Therapeutics Market Perspective (2017-2028)
2.2 Antibody Drug Conjugate Therapeutics Growth Trends by Region
2.2.1 Antibody Drug Conjugate Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Antibody Drug Conjugate Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Antibody Drug Conjugate Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Antibody Drug Conjugate Therapeutics Market Dynamics
2.3.1 Antibody Drug Conjugate Therapeutics Industry Trends
2.3.2 Antibody Drug Conjugate Therapeutics Market Drivers
2.3.3 Antibody Drug Conjugate Therapeutics Market Challenges
2.3.4 Antibody Drug Conjugate Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody Drug Conjugate Therapeutics Players by Revenue
3.1.1 Global Top Antibody Drug Conjugate Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Antibody Drug Conjugate Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antibody Drug Conjugate Therapeutics Revenue
3.4 Global Antibody Drug Conjugate Therapeutics Market Concentration Ratio
3.4.1 Global Antibody Drug Conjugate Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugate Therapeutics Revenue in 2021
3.5 Antibody Drug Conjugate Therapeutics Key Players Head office and Area Served
3.6 Key Players Antibody Drug Conjugate Therapeutics Product Solution and Service
3.7 Date of Enter into Antibody Drug Conjugate Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody Drug Conjugate Therapeutics Breakdown Data by Type
4.1 Global Antibody Drug Conjugate Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Type (2023-2028)
5 Antibody Drug Conjugate Therapeutics Breakdown Data by Application
5.1 Global Antibody Drug Conjugate Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Antibody Drug Conjugate Therapeutics Market Size (2017-2028)
6.2 North America Antibody Drug Conjugate Therapeutics Market Size by Country (2017-2022)
6.3 North America Antibody Drug Conjugate Therapeutics Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Antibody Drug Conjugate Therapeutics Market Size (2017-2028)
7.2 Europe Antibody Drug Conjugate Therapeutics Market Size by Country (2017-2022)
7.3 Europe Antibody Drug Conjugate Therapeutics Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Country (2017-2022)
8.3 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Antibody Drug Conjugate Therapeutics Market Size (2017-2028)
9.2 Latin America Antibody Drug Conjugate Therapeutics Market Size by Country (2017-2022)
9.3 Latin America Antibody Drug Conjugate Therapeutics Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Country (2017-2022)
10.3 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Bayer AG
11.1.1 Bayer AG Company Detail
11.1.2 Bayer AG Business Overview
11.1.3 Bayer AG Antibody Drug Conjugate Therapeutics Introduction
11.1.4 Bayer AG Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022)
11.1.5 Bayer AG Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Antibody Drug Conjugate Therapeutics Introduction
11.2.4 Pfizer Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022)
11.2.5 Pfizer Recent Development
11.3 Hoffman-Le Roche
11.3.1 Hoffman-Le Roche Company Detail
11.3.2 Hoffman-Le Roche Business Overview
11.3.3 Hoffman-Le Roche Antibody Drug Conjugate Therapeutics Introduction
11.3.4 Hoffman-Le Roche Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022)
11.3.5 Hoffman-Le Roche Recent Development
11.4 Seattle Genetics
11.4.1 Seattle Genetics Company Detail
11.4.2 Seattle Genetics Business Overview
11.4.3 Seattle Genetics Antibody Drug Conjugate Therapeutics Introduction
11.4.4 Seattle Genetics Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022)
11.4.5 Seattle Genetics Recent Development
11.5 ImmunoGen
11.5.1 ImmunoGen Company Detail
11.5.2 ImmunoGen Business Overview
11.5.3 ImmunoGen Antibody Drug Conjugate Therapeutics Introduction
11.5.4 ImmunoGen Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022)
11.5.5 ImmunoGen Recent Development
11.6 Genentech
11.6.1 Genentech Company Detail
11.6.2 Genentech Business Overview
11.6.3 Genentech Antibody Drug Conjugate Therapeutics Introduction
11.6.4 Genentech Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022)
11.6.5 Genentech Recent Development
11.7 Synthon Holding
11.7.1 Synthon Holding Company Detail
11.7.2 Synthon Holding Business Overview
11.7.3 Synthon Holding Antibody Drug Conjugate Therapeutics Introduction
11.7.4 Synthon Holding Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022)
11.7.5 Synthon Holding Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Detail
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Antibody Drug Conjugate Therapeutics Introduction
11.8.4 Sanofi Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022)
11.8.5 Sanofi Recent Development
11.9 Genmab
11.9.1 Genmab Company Detail
11.9.2 Genmab Business Overview
11.9.3 Genmab Antibody Drug Conjugate Therapeutics Introduction
11.9.4 Genmab Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022)
11.9.5 Genmab Recent Development
11.10 Amgen
11.10.1 Amgen Company Detail
11.10.2 Amgen Business Overview
11.10.3 Amgen Antibody Drug Conjugate Therapeutics Introduction
11.10.4 Amgen Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022)
11.10.5 Amgen Recent Development
11.11 Novartis
11.11.1 Novartis Company Detail
11.11.2 Novartis Business Overview
11.11.3 Novartis Antibody Drug Conjugate Therapeutics Introduction
11.11.4 Novartis Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022)
11.11.5 Novartis Recent Development
11.12 Eli Lilly
11.12.1 Eli Lilly Company Detail
11.12.2 Eli Lilly Business Overview
11.12.3 Eli Lilly Antibody Drug Conjugate Therapeutics Introduction
11.12.4 Eli Lilly Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022)
11.12.5 Eli Lilly Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Figures, Tables and Charts Available in Global Antibody Drug Conjugate Therapeutics Market Research Report 2022
List of TablesTable 1. Global Antibody Drug Conjugate Therapeutics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Mmunomedics Technology
Table 3. Key Players of Immunogen Technology
Table 4. Key Players of Seattle Genetics Technology
Table 5. Key Players of Others
Table 6. Global Antibody Drug Conjugate Therapeutics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Antibody Drug Conjugate Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Antibody Drug Conjugate Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 9. Global Antibody Drug Conjugate Therapeutics Market Share by Region (2017-2022)
Table 10. Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 11. Global Antibody Drug Conjugate Therapeutics Market Share by Region (2023-2028)
Table 12. Antibody Drug Conjugate Therapeutics Market Trends
Table 13. Antibody Drug Conjugate Therapeutics Market Drivers
Table 14. Antibody Drug Conjugate Therapeutics Market Challenges
Table 15. Antibody Drug Conjugate Therapeutics Market Restraints
Table 16. Global Antibody Drug Conjugate Therapeutics Revenue by Players (2017-2022) & (US$ Million)
Table 17. Global Antibody Drug Conjugate Therapeutics Market Share by Players (2017-2022)
Table 18. Global Top Antibody Drug Conjugate Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugate Therapeutics as of 2021)
Table 19. Ranking of Global Top Antibody Drug Conjugate Therapeutics Companies by Revenue (US$ Million) in 2021
Table 20. Global 5 Largest Players Market Share by Antibody Drug Conjugate Therapeutics Revenue (CR5 and HHI) & (2017-2022)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Antibody Drug Conjugate Therapeutics Product Solution and Service
Table 23. Date of Enter into Antibody Drug Conjugate Therapeutics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Antibody Drug Conjugate Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 26. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Type (2017-2022)
Table 27. Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 28. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Type (2023-2028)
Table 29. Global Antibody Drug Conjugate Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 30. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Application (2017-2022)
Table 31. Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 32. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Application (2023-2028)
Table 33. North America Antibody Drug Conjugate Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 34. North America Antibody Drug Conjugate Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 35. Europe Antibody Drug Conjugate Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 36. Europe Antibody Drug Conjugate Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 37. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 38. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Region (2023-2028) & (US$ Million)
Table 39. Latin America Antibody Drug Conjugate Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 40. Latin America Antibody Drug Conjugate Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 41. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 42. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 43. Bayer AG Company Detail
Table 44. Bayer AG Business Overview
Table 45. Bayer AG Antibody Drug Conjugate Therapeutics Product
Table 46. Bayer AG Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million)
Table 47. Bayer AG Recent Development
Table 48. Pfizer Company Detail
Table 49. Pfizer Business Overview
Table 50. Pfizer Antibody Drug Conjugate Therapeutics Product
Table 51. Pfizer Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million)
Table 52. Pfizer Recent Development
Table 53. Hoffman-Le Roche Company Detail
Table 54. Hoffman-Le Roche Business Overview
Table 55. Hoffman-Le Roche Antibody Drug Conjugate Therapeutics Product
Table 56. Hoffman-Le Roche Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million)
Table 57. Hoffman-Le Roche Recent Development
Table 58. Seattle Genetics Company Detail
Table 59. Seattle Genetics Business Overview
Table 60. Seattle Genetics Antibody Drug Conjugate Therapeutics Product
Table 61. Seattle Genetics Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million)
Table 62. Seattle Genetics Recent Development
Table 63. ImmunoGen Company Detail
Table 64. ImmunoGen Business Overview
Table 65. ImmunoGen Antibody Drug Conjugate Therapeutics Product
Table 66. ImmunoGen Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million)
Table 67. ImmunoGen Recent Development
Table 68. Genentech Company Detail
Table 69. Genentech Business Overview
Table 70. Genentech Antibody Drug Conjugate Therapeutics Product
Table 71. Genentech Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million)
Table 72. Genentech Recent Development
Table 73. Synthon Holding Company Detail
Table 74. Synthon Holding Business Overview
Table 75. Synthon Holding Antibody Drug Conjugate Therapeutics Product
Table 76. Synthon Holding Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million)
Table 77. Synthon Holding Recent Development
Table 78. Sanofi Company Detail
Table 79. Sanofi Business Overview
Table 80. Sanofi Antibody Drug Conjugate Therapeutics Product
Table 81. Sanofi Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million)
Table 82. Sanofi Recent Development
Table 83. Genmab Company Detail
Table 84. Genmab Business Overview
Table 85. Genmab Antibody Drug Conjugate Therapeutics Product
Table 86. Genmab Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million)
Table 87. Genmab Recent Development
Table 88. Amgen Company Detail
Table 89. Amgen Business Overview
Table 90. Amgen Antibody Drug Conjugate Therapeutics Product
Table 91. Amgen Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million)
Table 92. Amgen Recent Development
Table 93. Novartis Company Detail
Table 94. Novartis Business Overview
Table 95. Novartis Antibody Drug Conjugate TherapeuticsProduct
Table 96. Novartis Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million)
Table 97. Novartis Recent Development
Table 98. Eli Lilly Company Detail
Table 99. Eli Lilly Business Overview
Table 100. Eli Lilly Antibody Drug Conjugate TherapeuticsProduct
Table 101. Eli Lilly Revenue in Antibody Drug Conjugate Therapeutics Business (2017-2022) & (US$ Million)
Table 102. Eli Lilly Recent Development
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antibody Drug Conjugate Therapeutics Market Share by Type: 2021 VS 2028
Figure 2. Mmunomedics Technology Features
Figure 3. Immunogen Technology Features
Figure 4. Seattle Genetics Technology Features
Figure 5. Others Features
Figure 6. Global Antibody Drug Conjugate Therapeutics Market Share by Application in 2021 & 2028
Figure 7. Lymphoma Case Studies
Figure 8. Leukemia Case Studies
Figure 9. Multiple Myeloma Case Studies
Figure 10. Skin Cancer Case Studies
Figure 11. Colon Cancer Case Studies
Figure 12. Glioblastoma Case Studies
Figure 13. Pancreatic Cancer Case Studies
Figure 14. Prostate Cancer Case Studies
Figure 15. Solid Tumor Case Studies
Figure 16. Breast Cancer Case Studies
Figure 17. Antibody Drug Conjugate Therapeutics Report Years Considered
Figure 18. Global Antibody Drug Conjugate Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 19. Global Antibody Drug Conjugate Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 20. Global Antibody Drug Conjugate Therapeutics Market Share by Region: 2021 VS 2028
Figure 21. Global Antibody Drug Conjugate Therapeutics Market Share by Players in 2021
Figure 22. Global Top Antibody Drug Conjugate Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugate Therapeutics as of 2021)
Figure 23. The Top 10 and 5 Players Market Share by Antibody Drug Conjugate Therapeutics Revenue in 2021
Figure 24. North America Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. North America Antibody Drug Conjugate Therapeutics Market Share by Country (2017-2028)
Figure 26. United States Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Canada Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Europe Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Europe Antibody Drug Conjugate Therapeutics Market Share by Country (2017-2028)
Figure 30. Germany Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. France Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. U.K. Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Italy Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Russia Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Nordic Countries Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Share by Region (2017-2028)
Figure 38. China Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Japan Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. South Korea Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Southeast Asia Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. India Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Australia Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Latin America Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Latin America Antibody Drug Conjugate Therapeutics Market Share by Country (2017-2028)
Figure 46. Mexico Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Brazil Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Share by Country (2017-2028)
Figure 50. Turkey Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 51. Saudi Arabia Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 52. Bayer AG Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022)
Figure 53. Pfizer Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022)
Figure 54. Hoffman-Le Roche Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022)
Figure 55. Seattle Genetics Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022)
Figure 56. ImmunoGen Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022)
Figure 57. Genentech Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022)
Figure 58. Synthon Holding Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022)
Figure 59. Sanofi Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022)
Figure 60. Genmab Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022)
Figure 61. Amgen Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022)
Figure 62. Novartis Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022)
Figure 63. Eli Lilly Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2017-2022)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Keyplayers in Global Antibody Drug Conjugate Therapeutics Market Research Report 2022
Bayer AGPfizer
Hoffman-Le Roche
Seattle Genetics
ImmunoGen
Genentech
Synthon Holding
Sanofi
Genmab
Amgen
Novartis
Eli Lilly
Request Sample
Request Discount
